SCHEDULE: Deerfield Management Reduces Stake in BiomX Inc.

Deerfield Management and affiliated funds have reduced their beneficial ownership in BiomX Inc. to below 5%, triggering this Schedule 13D amendment.

Summary

• Deerfield Management and its affiliated funds (Deerfield Private Design Fund V, L.P. and Deerfield Healthcare Innovations Fund II, L.P.) sold a total of 309,878 shares of BiomX Inc. common stock between June 12 and June 16, 2026.
• As a result of these sales, the reporting persons now beneficially own 533,370 shares, representing approximately 4.70% of the company's outstanding common stock.
• The reporting persons have officially fallen below the 5% ownership threshold, which previously required them to file Schedule 13D disclosures.
• The sales were executed in the open market at weighted average prices ranging from $0.5538 to $0.5772 per share.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as slightly negative, as the departure of a major institutional holder from the 5% threshold often signals a reduction in long-term conviction or a shift in investment strategy.

Positives

• The reduction in stake by a major institutional investor provides clarity on their current position and removes the overhang of potential further large-scale selling related to this specific 13D filing requirement.

Negatives

• The divestment by a significant institutional holder may be perceived by the market as a lack of long-term confidence in the issuer's immediate growth prospects.
• The sale of shares at prices between $0.54 and $0.65 per share reflects a low valuation environment for the company's equity.

Risks

• The company's stock price remains sensitive to the trading activity of large institutional shareholders.
• The potential for further dilution exists due to outstanding warrants and options, though these are currently subject to a 9.99% beneficial ownership limitation.

Future Outlook

The reporting persons have ceased to be 5% beneficial owners, implying they are no longer required to file future amendments to this Schedule 13D unless their ownership position changes significantly again.

Industry Context

StockSavvy.ai notes that institutional divestment in the biotech sector is often a tactical move to rebalance portfolios or exit positions in companies facing long clinical development timelines or capital constraints.

Comparison to Industry Standards

• The exit from a 5% position is a standard regulatory procedure for institutional investors like Deerfield Management when reducing exposure to small-cap biotech equities.
• The trading prices ($0.55-$0.65) are consistent with the volatility often seen in micro-cap biotechnology stocks.

Stakeholder Impact

• Shareholders may experience increased volatility as the market adjusts to the change in institutional ownership levels.

Next Steps

• No further filings are required by these specific reporting persons under Section 13(d) unless their ownership again exceeds 5%.

Key Dates

Recommendation

The reduction of a major institutional stake is a signal to monitor, but does not inherently change the fundamental value of the company's pipeline; investors should hold until further clinical or financial updates are provided.

Keywords

BiomX, Deerfield Management, Schedule 13D, Institutional Divestment, Biotech, Equity Ownership